drugset / Trial / NCT03252002
Clinical Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Pharmacodynamic Effects of a Single and Multiple Oral BAY1101042 Tablet Doses in Healthy Male Subjects
RandomizedParallel-groupSingle-blindOther
Summary
To investigate the safety, tolerability, pharmacokinetics and effects of BAY1101042 in healthy male subjects after a single oral dose and multiple once daily dosing for 7 days
Timeline
- Start
- 2017-08-16
- Primary completion
- 2019-04-30
- Completion
- 2019-07-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BAY1101042 | Unknown | 5 mg | Oral |
| Subject | BAY1101042 | Unknown | 10 mg | Oral |
| Subject | BAY1101042 | Unknown | 20 mg | Oral |
| Subject | BAY1101042 | Unknown | 30 mg | Oral |
| Subject | BAY1101042 | Unknown | 40 mg | Oral |
| Subject | BAY1101042 | Unknown | 50 mg | Oral |
Indications
No indication recorded.